Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 9/20 | 0.59 |
| ▸ | F10 | P00742 | 8/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.56 |
| ▸ | C1S | P09871 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5009885 | 0.86 | LMNA (0.54) | F2F10LMNAMAPTSMN1; SMN2 | |
| SCHEMBL68851 | 0.84 | CYP4Z1 (0.62) | LMNAMAPTSMN1; SMN2CYP4Z1 | |
| Hydrochloric Acid SCHEMBL7301701 | 0.83 | F2 (0.62) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6393097 | 0.81 | ALDH1A1 (0.57) | LMNAMAPTSMN1; SMN2CYP4Z1 | |
| SCHEMBL393094 | 0.81 | LMNA (0.55) | LMNAMAPTSMN1; SMN2CYP4Z1 | |
| SCHEMBL2170299 | 0.81 | CA12 (0.61) | LMNAMAPTSMN1; SMN2CYP4Z1 | |
| SCHEMBL13262912 | 0.81 | L3MBTL1 (0.50) | LMNAMAPTSMN1; SMN2CYP4Z1 | |
| SCHEMBL3087853 | 0.81 | CYP4Z1 (0.54) | F2F10LMNAMAPTSMN1; SMN2 | |
| SCHEMBL15955709 | 0.79 | KMT2A (0.60) | LMNAMAPTSMN1; SMN2CYP4Z1 | |
| SCHEMBL1687054 | 0.79 | LMNA (0.54) | LMNAMAPTSMN1; SMN2CYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010130708-A9 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD (BM) | 2010-11-18 | — | — | US | disclosed |
| US-7119094-B1 | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade | WARNER-LAMBERT COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-6664255-B1 | 1-alkylamido-3-amino substituted; inhibiting serine proteases | PHARMACIA CORPORATION | 2003-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | F2 6/4885F10 48/4885PRSS1 8/4885 |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | F2 2849/4885F10 3318/4885PRSS1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.